The European Commission (EC) has granted approval to Takeda for ADZYNMA (recombinant ADAMTS13) - the first and only enzyme replacement therapy in the European Union (EU) for congenital thrombotic ...
Progress is being made on the British Army's Collective Training Transformation Programme (CTTP) that aims to deliver a Future Collective Training System (FCTS) in 2025. The Collective Training ...
Takeda has reported positive results from a phase 3 trial of its experimental therapy TAK-755 for ultra-rare disease congenital thrombotic thrombocytopenic purpura (cTTP), setting up regulatory ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...
A major milestone has been achieved under the Collective Training Transformation Programme (CTTP) for the British Army. The winner of the single-sourced contract will be selected in 2025. After slow ...
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...
"People living with cTTP experience serious, potentially fatal health challenges and have limited treatment options in the European Union," said Obi Umeh, M.D., M.Sc., Vice President, Franchise Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results